Fundraising Fox
Orna
Founded 2019 · 114 employees on LinkedIn · 3 known investors
Find your way into Orna
Sign up to see every warm intro you have to Orna
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Orna team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Orna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications. The company leverages proprietary drug development expertise in oRNA and LNP technology platforms.
Founders & leadership
JB
Joe BolenChief Executive Officer
JB
Joe Bolen, Ph.D.Chief Executive Officer
HD
Hope D'Oyley-Gay, JDChief Legal Officer
CL
Ciaran Lawlor, Ph.D.Chief Operating Officer
FN
Frank Neumann, M.D., Ph.D.Chief Medical Officer
SS
Siva SakhamuriChief Technology OfficerChief Technology Officer of Orna Therapeutics, Siva Sakhamuri brings biotechnology industry experience with expertise in manufacturing operations, process development, quality assurance, and GMP compliance across drug development lifecycles.
BS
Investors · 3
MPM BioImpactlisted by MPM BioImpactBoston · $1M – $15M
How we know: MPM BioImpact's portfolio page · a partner's Signal profile · Not right? Tell us
Funding
SEC filings, press & company announcements- Undisclosed amountSeed RoundJun 2022Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Related companies · 5
ロゴマーク：AIRNAAIRNA develops genetic medicines that use ADAR, a naturally occurring human protein, to precisely edit RNA and treat genetic diseases without permanently modifying DNA. The company targets diseases where the underlying genetic mechanism is well-established and difficult to address with existing therapeutic approaches.
RonatherapeuticsRona Therapeutics develops siRNA-based therapeutics using its GAIA platform to target metabolic and cardiovascular conditions including hypertriglyceridemia, obesity, ASCVD, and MASH. Its pipeline includes APOC3, INHBE, PCSK9-Lp(a), and angiotensinogen-targeting candidates for patients with cardiovascular and metabolic diseases.
Averna TherapeuticsAverna Therapeutics is a biotechnology company developing therapeutics. The page is a team bio profiling its CEO and board member.
Transcode TherapeuticsTransCode Therapeutics is an RNA-focused drug developer building oncology therapeutic candidates and diagnostics, using its TTX delivery technology across immunotherapy, gene editing, radiotherapy, and cancer vaccines. Its pipeline targets cancers such as pancreatic cancer through RNAi, RIG-I agonism, CRISPR, radioisotope delivery, and mRNA-based vaccines.
InnornaInnorna develops mRNA-based therapeutics built on a proprietary platform featuring a lipid library of over 100,000 ionizable lipid structures and targeted LNP delivery systems. The company's pipeline spans vaccines, protein replacement therapies for chronic metabolic diseases, and in vivo immunotherapies for autoimmune conditions, with four candidates in clinical trials.
Companies working in the same space as Orna.
In the news
Frequently asked questions
- What does Orna do?
- Orna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications. The company leverages proprietary drug development expertise in oRNA and LNP technology platforms.
- Who are Orna's investors?
- Orna's investors include Astellas Venture Management LLC, MPM BioImpact, Taiho Ventures, LLC.